You Y Nancy, Rustin Rudolph B, Sullivan James D
Department of Surgical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
Mt. Pleasant, SC, USA.
Surg Oncol. 2015 Jun;24(2):61-6. doi: 10.1016/j.suronc.2015.02.001. Epub 2015 Feb 14.
Advances in molecular biology have enabled identification of tumor biomarkers that allow for individualized risk assessment for patients with cancer. Molecular predictors of clinical outcome can help inform discussion regarding the role of adjuvant chemotherapy in patients with resected colon cancer, such as those with stage II colon cancer in which the benefit of adjuvant therapy is controversial or those with stage III colon cancer who may have a lower risk of recurrence and less absolute benefit from oxaliplatin therapy. This article summarizes the data surrounding the development, validation, and clinical and economic utility of the Oncotype DX(®) colon cancer assay, a multigene expression assay validated to independently predict recurrence risk in patients with stage II and III colon cancer beyond traditional factors.
分子生物学的进展使得能够识别肿瘤生物标志物，从而对癌症患者进行个性化风险评估。临床结局的分子预测指标有助于为关于辅助化疗在已切除结肠癌患者（如Ⅱ期结肠癌患者，辅助治疗的获益存在争议；或Ⅲ期结肠癌患者，其复发风险可能较低，从奥沙利铂治疗中获得的绝对获益较少）中的作用的讨论提供信息。本文总结了关于Oncotype DX®结肠癌检测的开发、验证以及临床和经济效用的数据，这是一种多基因表达检测，经验证可独立预测Ⅱ期和Ⅲ期结肠癌患者超出传统因素的复发风险。
